Non-Hodgkin Lymphoma (NHL)

Latest News

DLBCL | Image Credit: Image Credit: laszlo-stock.adobe.com
ViPOR: Novel Targeted Therapy Combination Shows Potential in Relapsed DLBCL

July 1st 2024

The 5 agents in ViPOR—including venetoclax and lenalidomide—worked better together in a phase 1b/2 trial than they previously have, individually, in treating patients with certain diffuse large B-cell lymphoma (DLBCL) subtypes.

FDA approved | Image credit: ArtEternal – stock.adobe.com
Epcoritamab Gets Label Expansion for Difficult-to-Treat R/R Follicular Lymphoma

June 27th 2024

microscopic image of DLBCL | Image Credit: David A Litman-stock.adobe.com
Polatuzumab Vedotin: Review Spotlights Its Use, Promise in DLBCL

June 17th 2024

Medical technology | Image credit: ipopba - stock.adobe.com
Dr Catherine Diefenbach on the Evolving DLBCL Treatment Landscape

June 14th 2024

Case Reports: Managing DLBCL Associated With Papillary Thyroid Carcinoma
Case Reports: Managing DLBCL Associated With Papillary Thyroid Carcinoma

June 12th 2024

Continuing Medical Education
July 1st 2024

Recent Advances in BCMA-Directed Treatment in Multiple Myeloma: Insights and Application for Managed Care

1.0 Credits / Hematologic Cancer, Oncology
July 1st 2024

Keeping Pace With New Developments in Multiple Myeloma: Updates and Strategies to Optimize Bispecific Antibodies and CAR T-Cell Therapy

1.5 Credits / Oncology, Hematology, Hematologic Cancer
July 1st 2024

Addressing the Gaps and Clinical Challenges in Chronic Lymphocytic Leukemia: Updates and Strategies for Managed Care

1.5 Credits / Hematology, Hematologic Cancer, Oncology

More News

Lymphoma cells | Image credit: LASZLO - stock.adobe.com
September 22nd 2023

Salvage RT Shows Local Control in LBCL After CAR T-Cell Therapy Failure

Rose McNulty
Salvage radiation therapy (RT) showed efficacy in local control of relapsed or refractory large B-cell lymphoma (LBCL) following CD19-targeted chimeric antigen receptor (CAR) T-cell therapy failure.
Diffuse large B-cell lymphoma | Image credit: David A Litman - stock.adobe.com
September 21st 2023

Subcutaneous Epcoritamab Elicits Durable Responses in R/R LBCL

Kristi Rosa
Subcutaneous epcoritamab produced deep and durable complete remissions in patients with relapsed or refractory (R/R) large B-cell lymphoma (LBCL), with complete responders having favorable long-term outcomes, according to updated data from the phase 1/2 EPCORE NHL-1 trial.
CT machine | Image credit: MyPixelArtStudios - stock.adobe.com
September 15th 2023

Novel PET-Based Radiomics Signature Predicts CAR T Efficacy in DLBCL

Rose McNulty
A PET-based radiomics signature was able to predict the efficacy of chimeric antigen receptor (CAR) T-cell therapy and performed better than conventional PET biomarkers in patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
Blood cells | Image credit: Катерина Євтехова - stock.adobe.com
September 7th 2023

Review Highlights Knowledge Gaps in Lymphoma Treatment Outcomes in AYAs

Rose McNulty
The review summarized existing evidence around short- and long-term treatment-related toxicities among adolescents and young adults (AYAs), as well as gaps in care guidelines for AYA survivors of lymphoma.
Blood flowing
August 18th 2023

EMA Accepts Marketing Application for Odronextamab in R/R DLBCL, Follicular Lymphoma

Rose McNulty
The European Medicines Agency (EMA) has accepted a Marketing Authorization Application (MAA) for odronextamab for relapsed/refractory (R/R) follicular lymphoma (FL) or R/R diffuse large B-cell lymphoma (DLBCL) following disease progression after at least 2 prior lines of systemic therapy.
CAR T-cell therapy
August 11th 2023

Axi-Cel Extends Survival vs Standard of Care for R/R LBCL

Rose McNulty
An overall survival (OS analysis of the phase 3 ZUMA-7 trial demonstrated longer OS in patients treated with axicabtagene ciloleucel (axi-cel) vs the standard of care for early relapsed or refractory (R/R) large B-cell lymphoma (LBCL).
Senior sad man leans on a cane while sitting on sofa: © LIGHTFIELD STUDIOS - stock.adobe.com
August 1st 2023

Despite Novelty, Fluid Overload–Associated LBCL Has Distinguishing Features

Jared Kaltwasser
Investigators said the fact that their patient was 82 years old was one reason to suspect fluid overload–associated large B-cell lymphoma (LBCL).
Doctor holding in his hands two silicone implants. Female patient trying to touch them: © Yakobchuk Olena - stock.adobe.com
July 31st 2023

Amid Increasing Breast Implant–Related EBV+ DLBCL Cases, Researchers Share Insights on the Disease

Jaime Rosenberg
Recognition of the association between breast implants and lymphomas has been notable since the 1990s, although the association has been limited to breast implant–associated anaplastic large cell lymphoma and not Epstein-Barr virus (EBV).
Blood vial and hepatitis B | Image Credit: © alexskopje - stock.adobe.com
July 29th 2023

Treated Hepatitis B Infection May Be a Positive Prognostic Factor in Patients With DLBCL

Gianna Melillo
Those with the infection who underwent treatment exhibited improved outcomes compared with patients without the infection.
Endocrinology doctor consulting lymphoma patient with sore neck, aching swollen lymph nodes, throat pain, laryngitis, hodgkin symptoms. Healthcare specialist medical appointment in clinic office: © DC Studio - stock.adobe.com
July 27th 2023

Review Details Current Understanding, Future Directions of DLBCL in Patients With HIV

Gianna Melillo
Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin subtype in individuals living with HIV.
Heart and DNA Image
July 22nd 2023

In DLBCL Treatment, Cardiovascular Comorbidities Warrant Careful Consideration

Jared Kaltwasser
The most common treatments come with significant cardiovascular risk, but study investigators suggest newer options might offer a more favorable risk profile.
Symbol of pancreatic cancer. Purple awareness ribbon: © Vitalii Vodolazskyi - stock.adobe.com
July 18th 2023

In Pancreatic DLBCL, Older Age, Distant Stage, Lack of Surgery Lead to Worse Outcomes

Jared Kaltwasser
Surgery can be difficult in such cases of diffuse large B-cell lymphoma (DLBCL), but it leads to significant better outcomes, study authors said.
Colorful cell interaction - tumor cell surrounded with immune cells (Generative AI): © Nevio - stock.adobe.com
July 11th 2023

Lymph Node Fibroblasts May Suppress T-Cell Function in DLBCL

Gianna Melillo
These findings from research into diffuse large B cell lymphoma (DLBCL) are based on analyses of human patients and a murine model.
PET/CT is a nuclear medicine device that uses a combination of PET (Positron Emission Tomography) and Computed Tomography technology to diagnose cancer. Brain and nervous system myocardial ischemia: © workphoto - stock.adobe.com
July 8th 2023

Complicated Case of DLBCL Shows Limits of 18F-FDG PET/CT Imaging

Jared Kaltwasser
Investigators said it is important for clinicians to interpret scans with knowledge of case-specific context for patients with diffuse large B-cell lymphoma (DLBCL).
White blood cells in leukemia, AI Generative: © Катерина Євтехова - stock.adobe.com
July 5th 2023

Evolutionary Dynamics Drive Behind Outcomes in Late DLBCL Relapses

Jared Kaltwasser
Serial biopsies help explain why patients with late relapses of diffuse large B-cell lymphoma (DLBCL) fare better than those with early relapses.
Topline Results Show Epcoritamab Offers 82% Response Rate in R/R Follicular Lymphoma
June 28th 2023

Topline Results Show Epcoritamab Offers 82% Response Rate in R/R Follicular Lymphoma

Mary Caffrey
The bispecific antibody received an accelerated approval in May to treat patients with R/R diffuse large B-cell lymphoma.
Finding solutions to complex cases from several perspectives. High angle shot of a group of medical practitioners having a discussion together in a hospital: © Kirsten D/peopleimages.com - stock.adobe.com
June 27th 2023

Patient Complaining of Abdominal Pain Found to Have Unusual Case of DLBCL

Jared Kaltwasser
The patient was put on chemotherapy, but then underwent surgical resection following an accident at home.
New Epcoritamab Data Show Strong Results in B-Cell Lymphomas
June 22nd 2023

New Epcoritamab Data Show Strong Results in B-Cell Lymphomas

Jared Kaltwasser
Data presented at the 2023 European Hematology Association Annual Meeting showed positive outcomes in patients with follicular lymphoma and large B-cell lymphoma, and further evaluation in diffuse large B-cell lymphoma is ongoing.
researchers in a lab
June 17th 2023

Epcoritamab Sparks Durable Responses in Phase 1/2 LBCL Trial

Jared Kaltwasser
At a median follow-up of 10.7 months, the overall response rate was 63.1%.
chest pain
June 16th 2023

Investigators Find DLBCL When Probing Apparent Intramural Hematoma

Jared Kaltwasser
The case report highlights the importance of considering diffuse large B-cell lymphoma (DLBCL) when evaluating patients with persistent periaortic fluid collections.
depressed older man sitting with his head in his hand
June 8th 2023

Preexisting Mental Health Disorders Worsen DLBCL Prognosis

Laura Joszt, MA
Patients with depression, anxiety, or both at the time of diagnosis of diffuse large B-cell lymphoma (DLBCL) have worse overall survival and lymphoma-specific survival.
science background
June 7th 2023

Review: Advances in the Understanding of DLBCL Immunology Could Spark Novel Therapies

Jared Kaltwasser
New therapies could potentially target immune systems at play in certain types of diffuse large B-cell lymphoma.
FDA approved
May 19th 2023

Epcoritamab Approved by FDA to Treat R/R DLBCL

Mary Caffrey
Approval for the T-cell–engaging bispecific antibody came today from the FDA.
ASH 2022: Bispecific Antibodies
February 4th 2023

ASH 2022: Bispecific Antibodies

Mary Caffrey Hayden E. Klein
Coverage from the 64th Annual American Society of Hematology Meeting and Exposition, December 10-13, 2022, New Orleans, Louisiana.
Graphic with the words "Top 5 Clinical Spotlight Interviews of 2022"
December 29th 2022

Top 5 Clinical Spotlight Interviews of 2022

AJMC Staff
Throughout 2022, expert interviews on clinical topics covered cytogenetics in multiple myeloma, access to better treatments in diffuse large B-cell lymphoma, and challenges with devices in chronic obstructive pulmonary disease.
<123>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
CH LogoCenter for Biosimilars Logo